Repurposing Old Drugs into New Epigenetic Inhibitors: Promising Candidates for Cancer Treatment?
Open Access
- 29 April 2020
- journal article
- review article
- Published by MDPI AG in Pharmaceutics
- Vol. 12 (5) , 410
Abstract
Epigenetic alterations, as a cancer hallmark, are associated with cancer initiation, progression and aggressiveness. Considering, however, that these alterations are reversible, drugs that target epigenetic machinery may have an inhibitory effect upon cancer treatment. The traditional drug discovery pathway is time-consuming and expensive, and thus, new and more effective strategies are required. Drug Repurposing (DR) comprises the discovery of a new medical indication for a drug that is approved for another indication, which has been recalled, that was not accepted or failed to prove efficacy. DR presents several advantages, mainly reduced resources, absence of the initial target discovery process and the reduced time necessary for the drug to be commercially available. There are numerous old drugs that are under study as repurposed epigenetic inhibitors which have demonstrated promising results in in vitro tumor models. Herein, we summarize the DR process and explore several repurposed drugs with different epigenetic targets that constitute promising candidates for cancer treatment, highlighting their mechanisms of action.Keywords
Funding Information
- Fundação para a Ciência e a Tecnologia (29030/2017, UIDB/50011/2020, UIDP/50011/2020)
This publication has 115 references indexed in Scilit:
- Inhibition of LSD1 sensitizes glioblastoma cells to histone deacetylase inhibitorsNeuro-Oncology, 2011
- Progression to metastatic stage in a cellular model of prostate cancer is associated with methylation of the androgen receptor gene and transcriptional suppression of the insulin-like growth factor-I receptor geneExperimental Cell Research, 2010
- Inhibition of Lysine Acetyltransferase KAT3B/p300 Activity by a Naturally Occurring Hydroxynaphthoquinone, PlumbaginJournal of Biological Chemistry, 2009
- Modulation of DNA Methylation by a Sesquiterpene Lactone ParthenolideThe Journal of Pharmacology and Experimental Therapeutics, 2009
- Histone deacetylases 1, 2 and 3 are highly expressed in prostate cancer and HDAC2 expression is associated with shorter PSA relapse time after radical prostatectomyBritish Journal of Cancer, 2008
- Procaine inhibits the proliferation and DNA methylation in human hepatoma cellsHepatology International, 2007
- Chromatin Modifications and Their FunctionCell, 2007
- Histone H3 Lysine 4 Demethylation Is a Target of Nonselective Antidepressive MedicationsChemistry & Biology, 2006
- LSD1 demethylates repressive histone marks to promote androgen-receptor-dependent transcriptionNature, 2005
- Drug repositioning: identifying and developing new uses for existing drugsNature Reviews Drug Discovery, 2004